New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK
Metrics: PDF 995 views | HTML 1048 views | ?
Daniela Di Paolo1, D. Yang2, Fabio Pastorino1, Laura Emionite3, Michele Cilli3, Antonio Daga4, Elisa Destafanis1,6, Annarita Di Fiore1, Francesca Piaggio1, Chiara Brignole1, Xiaobao Xu2, Chris Liang5, James Gibbons5, Mirco Ponzoni1,*, Patrizia Perri1,*
1Laboratorio di Oncologia, Istituto G. Gaslini, Genoa, Italy
2Sundia MediTech Company, Ltd., Shangai, China
3Animal Facility, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
4Laboratorio Trasferimento Genico, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
5Xcovery LLC, West Palm Beach, FL, USA
6Present address: Centre for Inherited Cardiovascular, IRCCS Politecnico San Matteo, Pavia, Italy
*These authors have contributed equally to this work
M. Ponzoni, e-mail: firstname.lastname@example.org
P. Perri, e-mail: email@example.com
Keywords: neuroblastoma, ALK-inhibitor, X-396, RNA-interference, targeted nanoliposomes
Received: March 10, 2015 Accepted: June 09, 2015 Published: June 20, 2015
Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients.
We tested: the activity of the novel ALK-inhibitor X-396 administered alone or in combination with Targeted Liposomes carrying ALK-siRNAs (TL[ALK-siRNA]) that are active irrespective of ALK gene mutational status; the pharmacokinetic profiles and the biodistribution of X-396; the efficacy of X-396 versus crizotinib treatment in NB xenografts; whether the combination of X-396 with the TL[ALK-siRNA] could promote long-term survival in NB mouse models.
X-396 revealed good bioavailability, moderate half-life, high mean plasma and tumor concentrations. X-396 was more effective than crizotinib in inhibiting in vitro cell proliferation of NB cells and in reducing tumor volume in subcutaneous NB models in a dose-dependent manner.
In orthotopic NB xenografts, X-396 significantly increased life span independently of the ALK mutation status. In combination studies, all effects were significantly improved in the mice treated with TL[ALK-siRNA] and X-396 compared to mice receiving the single agents.
Our findings provide a rational basis to design innovative molecular-based treatment combinations for clinical application in ALK-driven NB tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.